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Rheumatoid Cachexia: causes, 
significance and possible interventions
George S. Metsios1,2, Antonis Stavropoulos-Kalinoglou1,2, 
Yiannis Koutedakis3, George D. Kitas1,4
A B S T R A C T
Rheumatoid arthritis is a chronic autoimmune disease characterised by joint pain and 
stiffness but also systemic mutli-organ involvement. Several features are due to exces-
sive production of inflammatory cytokines, particularly tumour necrosis factor alpha, 
interleukin-1 and interleukin-6. These are implicated in both local synovial inflam-
mation, which causes joint destruction, but also systemic inflammation, which can 
cause loss of body cell mass, amongst other phenomena. Body cell mass breakdown 
in rheumatoid arthritis leads to the classical, but largely ignored, metabolic abnor-
mality known as rheumatoid cachexia. Cachexia is a very strong predictor of adverse 
functional outcome and death in many disease states. In this review we highlight the 
mechanisms linked with rheumatoid cachexia and discuss possible interventions that 
may limit this in patients with rheumatoid arthritis.
I N T R O D U C T I O N
With an estimated prevalence of 0.5–1% in Europe and North America (cur-
rently 0.8% of the adult population in the UK) [1], rheumatoid arthritis (RA) is the 
commonest chronic inflammatory joint disease and affects more women than men. 
The cause of RA remains unknown, but genetic predisposition, aberrant immune 
responses, and physical stress have, amongst others, been identified as significant 
factors in its pathogenesis.
The main site of inflammation in RA is the synovial membrane (synovium). Rheu-
matoid synovium becomes a hyperplastic, highly vascularised tissue heavily infiltrated 
by chronic inflammatory cells. RA is genetically linked to certain major histocom-
patibility complex class II antigens (HLA-DRB1*0404 and 0401). Class II molecules 
present antigenic peptides to CD4+ T cells, and this suggests that RA is caused by a, 
yet unidentified, antigen. CD4+ activated T lymphocytes are central to rheumatoid 
chronic synovitis. They can stimulate monocytes, macrophages and synovial fibroblasts 
to produce cytokines such as interleukins (IL) -1 and 6 and tumour necrosis factor 
alpha (TNFá). Through cell-surface signaling (e.g. CD69 and CD11 or CD40 ligand 
and CD28) or through the release of specific cytokines (e.g. interferon gamma, IL-17 
and others) they also regulate the secretion of matrix metalloproteinases (MMPs) and 
other effector molecules (e.g. free radicals) from macrophages and the stimulation of B 
cells to produce antibodies. Activated inflammatory cells and their products may have 
multiple effects. They can promote further inflammatory cell recruitment by activating 
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endothelial cells to express adhesion molecules and by releas-
ing chemokines such as IL-8: this could, in part, explain the 
flares and overall chronicity of the disease. They can stimulate 
neo-angiogenesis, which would explain the increased vascular-
ity of the inflamed synovium. They may be involved in cartilage 
and bone degradation through multiple mechanisms including 
MMP and free radical release, and direct effects on osteoclasts 
and chondrocytes, which can explain the erosive damage to 
the joint [2]. The main inflammatory cytokines, IL-1, IL-6 and 
TNFá, also have important effects on distant organs, e.g. the 
liver, muscle, fat and vascular endothelium. These systemic 
effects explain several other phenomena, including the acute 
phase response (which is used for monitoring the inflamma-
tory activity of RA in every-day clinical practice), rheumatoid 
cachexia [3] (the loss of lean body mass), and a constellation 
of effects, which may collectively promote atherogenesis [4,5] 
(e.g. dyslipidaemia, insulin resistance, thrombogenesis, and 
endothelial dysfunction amongst others). It is interesting that 
the extent of inflammatory activity in RA, assessed by the 
acute phase response (e.g. erythrocyte sedimentation rate, 
or C-reactive protein), clinical measures (e.g. joint swelling) 
or indices combining both, associates not only with the extent 
of joint damage and disability, but also with cardiovascular 
events and death [6-10]. Effective control of inflammatory 
activity using disease-modifying anti-rheumatic drugs, may, 
in contrast, confer functional and survival benefits [11-15], 
but there may be significant differences between individual 
drugs, requiring further investigation.
The metabolic alterations associated to prolonged over-
production of cytokines in RA are significant. Nearly 2/3 of 
all individuals with RA experience a metabolic abnormality 
accompanied by wasting of muscle mass, with the presence of 
stable or even increased fat mass, and no weight loss [16]. This 
is referred to as rheumatoid cachexia (RC). This condition is 
developed in RA with no clinical evidence of malabsorption or 
impaired liver or renal function [17], and the exact underlying 
mechanisms are not yet entirely clear. Nevertheless, possible 
contributing factors may be the overproduction of TNFá [16], 
the synergy of TNFá with IL-1b, other cytokines, hormones 
and transcription factors active on muscle [18], reduced pe-
ripheral insulin action [19,20], and physical inactivity [3] (Fig. 
1). In this review, we concentrate on the definition of RC and 
the most important mechanisms involved in its pathogenesis, 
i.e. cytokine overdrive and physical inactivity, both of which 
may be subject to successful therapeutic intervention.
R H E U M A T O I D  C A C H E X I A :  D E F I N I T I O N  
A N D  C O N S E Q U E N C E S
Skeletal muscle mass along with visceral and immune sys-
tem mass constitute the body cell mass (BCM). This accounts 
for about 95% of the total metabolic activity of the human 
body [21]. Loss of BCM leads to reduced energy expenditure, 
compromised muscular strength, balance and movement abil-
ity, and impaired immune function [22]. BCM losses greater 
than 40% of baseline values associate with almost certain 
death [23,24].
In general, BCM losses are associated with qualitative 
and quantitative declines in skeletal muscle mass, termed 
sarcopenia, and occur with normal aging. Indeed, signifi-
cant differences have been reported when BCM of normal 
older adults was compared to that of younger individuals 
[25]. Although sarcopenia does not require the presence of 
a disease, this age-related loss of BCM and skeletal muscle 
mass can be significantly enhanced by the presence of chronic 
diseases [26].
RA can occur at any age, but the overwhelming majority 
of prevalent RA cases are predominantly middle-aged and 
elderly individuals, so some age-related sarcopenia would be 
expected. However, RA patients experience an accelerated 
involuntary BCM loss, predominantly in the skeletal muscle 
[16], over and above that normally expected. This condition, 
which is clearly different from sarcopenia, is termed cachexia 
and connotes the loss of BCM occurring due to the illness 
rather than normal aging [27]. The term RC is used specifically 
for patients with RA and dates back to the original description 
of the disease [28]. In RA, BCM loss has been associated with 
muscle weakness and limited mobility, thus reduced functional 
ability and quality of life [29,30]. However, RC in RA is also 
accompanied by little or no weight loss in the presence of 
stable or increased fat mass: this has led to the introduction 
of the term “rheumatoid cachectic obesity” [3] and may be of 
FIGURE 1. Contributing Factors to the Development and Pro-
gression of Rheumatoid Cachexia.
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great importance. It essentially suggests that RA patients with 
normal or near normal body mass index (BMI) may have a 
significantly higher fat component in their body composition 
than age, sex and BMI-matched controls. This increased fat 
mass may be responsible for intensification and perpetuation 
of the inflammatory response, as adipose tissue represents 
one of the predominant sources of IL-6 in the body [31,32]. It 
may also relate to the well-described association of RA with 
increased overall and cardiovascular mortality [4].
R H E U M A T O I D  C A C H E X I A  A N D  E N E R G Y  
E X P E N D I T U R E
Daily energy expenditure (DEE) consists of resting energy 
expenditure (REE) (i.e. the amount of energy required for 
the body to sustain physiological processes at rest), energy 
expended for physical activity and bodily movement in general, 
and the thermic effect of feeding. REE accounts for 70% 
of DEE [33] and in normal individuals is highly depended 
on BCM [34]. In RA patients, however, the relation between 
BCM and REE seems to be altered. Such individuals, exhibit 
significantly decreased BCM with increased REE, accompa-
nied by increased whole-body protein catabolism. These are 
both driven by pro-inflammatory cytokines and their co-exist-
ence leads to RC [3].
S P E C I F I C  M E C H A N I S M S
The exact pathophysiological mechanisms underlying the 
development of RC are not yet fully understood. They include: 
a) excessive cytokine production, b) reduced peripheral insulin 
action, and c) physical inactivity.
C Y T O K I N E S
Cytokines are extracellular peptides influencing cell 
proliferation, migration and behaviour by acting upon them 
through specific receptor interactions. They are produced 
mainly from cells of the immune system such as monocytes/
macrophages and T-cells, but also skeletal muscle, fat and 
other tissues [35,2]. Although their key physiological role is 
homeostasis, activation of inflammatory mechanisms, repair 
and remodelling of damaged tissue, they are also the main 
orchestrators of the dysregulated responses seen in chronic 
inflammatory autoimmune diseases. The pro-inflammatory 
cytokines TNFá, IL-1b, and IL-6 are key to the development 
and perpetuation of the local and systemic inflammatory re-
sponse observed in RA. The predominant stimuli, sources and 
functional effects of IL-1 and TNFá are shown in Figure 2.
TNFá was first identified as ‘cachectin’ after its catabolic 
function. TNFá is involved in biological processes which go 
well beyond its pro-inflammatory functions [36], possibly due 
to the differential bioactivities of its soluble and trans-mem-
brane form [37]. TNFá is intimately involved in the metabolic 
abnormalities observed in RA, leading to significant skeletal 
muscle wasting and augmentation in energy expenditure and, 
thus, the occurrence of RC. Concurrent overproduction of 
TNFá and IL-1â during the acute-phase response in RA 
causes several systemic changes which, in turn, contribute to 
metabolic alterations [38]. They significantly affect muscle 
metabolism by enhancing protein catabolic processes [18]. 
Since the within the muscle balance of protein degradation and 
re-synthesis is not maintained, continuing cytokine overdrive 
will tip the balance towards protein breakdown [3]. This is in 
line with more recent data which revealed that TNFá and IL-
1 contribute to central nervous system side affects, increase 
muscle metabolism and bone marrow suppression, all of which 
are present in chronic inflammatory diseases [39].
The exact biochemical mechanisms by which skeletal mus-
cles undergo rapid protein loss in response to cytokines, have 
been frequently studied in vivo and in vitro given that muscle 
wasting is present in many serious diseases, such as cancer, 
renal failure, HIV and RA. Enhanced muscle proteinolysis 
seems to occur through the ubiquitin-proteasome pathway 
[40], as protein catabolism is targeted by conjugation to ubiq-
uitin [41]. In some inflammatory diseases, TNFá is thought 
to stimulate muscle catabolism via an NF-kappaB-dependent 
process that increases ubiquitin conjugation to muscle pro-
teins [42]. Through a cascade of processes, TNFá bound to 
surface receptors activates the transcriptional NF-kB pathway 
leading to the degradation of a protein I-kBa that inhibits 
NF-kB [43,44]. NF-kB is one of the most important signal 
transduction pathways in RA as it is engaged in mediating the 
production of IL-1 and TNFá and their effects on target cells 
after they have bound to cell surface receptors [39].
TNFá may also cause reduced protein synthesis through 
reduced insulin action, as it interferes with the insulin recep-
tor signalling pathway [45]. Several studies suggest that RA 
associates with reduced peripheral insulin action [19,20]. 
Insulin triggers intracellular enzyme activity that facilitates 
protein synthesis by increased amino acid transport through 
the plasma membrane, RNA cellular levels, and protein for-
mation by ribosomes [46].
FIGURE 2. Effects of IL-1 and TNFα in inflammation.
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administration of TNFá and IL-1 blocking agents, whereas 
anti-IL-6 therapy will soon also become available. In the 
meantime, enhanced physical activity and lifestyle changes 
may be a reasonable route to take in RA patients, as it is 
safe, associates with several other health benefits, and with 
concerted effort can be provided by health care systems and 
achieved by RA patients.
In normal individuals, health status is highly influenced 
by lifestyle and physical activity. Active lifestyle and increased 
levels of physical activity have been associated with decreased 
body fat, increased aerobic capacity, muscular strength and 
overall health [53]; even with increased life expectancy [54] 
while sedentary lifestyle and physical inactivity have the op-
posite results [55].
Patients with RA tend to lead a sedentary lifestyle and 
refrain from physical activity, mainly due to joint pain and 
inflammation, and for fear of aggravating their disease [16]. 
Consequently, they experience many, if not all of the health 
problems related to sedentarity. The presence of chronic in-
flammation further worsens this. Indeed, in patients with RA, 
deficits of up to 40% in aerobic capacity have been reported; 
muscle strength in isometric knee extension is 18–60 % lower 
and flexibility in joints suffering from RA is 20–60 % lower. 
In functional tasks, such as walking a certain distance or 
climbing stairs, studies have reported deficits of up to 60% 
in RA patients. Also increased energy expenditure (30-50 % 
more than healthy peers) ventilation (up to 27%) and heart 
rate (19%) at sub-maximal workloads, often result in earlier 
onset of fatigue, limited endurance and poor neuromuscular 
control. Thus most of the patients stop exercise due to factors 
related to exercise intolerance and not pain or other factors 
related to the disease [56].
Most researchers who studied the effects of exercise 
on RA patients, used intensities of 60-80 % and duration 
of 15-60 min, 3-4 times a week. Results demonstrate 12-21 
% improvements in cardiovascular performance and 0-55% 
increase in strength depending on the type of exercise, as 
well as significant increases in flexibility [57]. Even though 
many participants in these studies were de-conditioned at the 
beginning of the experiments, they were able to exercise at 
levels necessary to produce a training effect. An unexpected 
effect of exercise is the reduced joint swelling experienced by 
some persons after aerobic exercise. Moreover, individuals 
who exercised more than five hours per week experienced less 
progression of joint damage, less hospitalization, less work 
disability and no difference in clinically active joints than 
those who did not exercise [58].
Specifically for the prevention of RC, strength training is 
the most important non-pharmacological treatment. Muscle 
growth and/or maintenance require sufficient physiological 
stimuli. The beneficial effects of strength exercise in the 
maintenance of adequate age-related strength levels have 
been well-established. Strength training programs elicit 
IL-1 and IL-6 have also been proposed as mediators of 
muscle protein degradation in different catabolic conditions. 
However, the proteinolytic mechanisms involved are not yet 
fully understood [47,48].
Human studies demonstrate the association between ex-
cess TNFá and IL-1â with RC, but have failed to directly link 
these pro-inflammatory cytokines with the exact mechanism 
of muscle wasting. By blocking either TNFá with a recom-
binant soluble TNFá receptor or IL-1â with a recombinant 
IL-1 receptor antagonist, it was found that blocking TNFá 
alone only moderately reduced the loss of skeletal muscle 
weight. Blocking both TNFá and IL-1â was more effective 
in preventing undue muscle wasting, indicating that TNFá is 
an important element in this process, but possibly not on its 
own [49]. It remains unclear whether these cytokines promote 
protein degradation or restrain protein synthesis, and whether 
their effects are direct or through a network of many other 
hormones and cytokines.
R E D U C E D  P H Y S I C A L  A C T I V I T Y
RA is a chronic progressive disease of the joints associated 
with systemic involvement, significant morbidity, deformity, 
and diminished quality of life. Structural damage in the 
musculoskeletal system can be developed within the first two 
years of the disease [50]. Pain, joint stiffness and inflamma-
tion, fatigue and reduced muscle strength are all elements of 
RA symptomatology [51]. Physical activity can therefore be 
significantly compromised in RA patients.
In general, reduced physical activity is associated with an 
alteration in normal physiological processes leading to muscle 
atrophy, loss of ability for exercise, insulin resistance, and 
energy balance variations. Bed-rest studies reveal that lack of 
effective muscle stimuli decreases the turnover rates of muscle 
and whole-body proteins, with a prevailing inhibition of pro-
tein synthesis [52]. These factors might also be contributing 
to the initiation and/or progression of RC.
P O S S I B L E  I N T E R V E N T I O N S
Since the exact causes of RC are not fully delineated, no 
definite preventive or therapeutic strategies have been tested 
to-date. The introduction of anti-TNFá therapy may provide 
an opportunity to address this problem, but this requires 
prospective assessment. It is a common clinical observation 
that RA patients receiving anti-TNF therapy commonly and 
rapidly put on weight. It remains unclear whether this is due 
to a significant change to their body composition and reversal 
of RC, i.e. whether it is predominantly due to muscle gain or 
fat gain. Ongoing research in our laboratory investigates the 
effects of anti-TNFá administration on body composition 
(body fat and muscle mass) and REE and we will hopefully 
be able to clarify this. Future directions may involve the co-
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significant improvements in muscle strength levels in healthy 
adults [59] even in healthy elderly adults [60]. In RA, long-
term high-intensity exercise programs are more effective 
than physiotherapy care in improving functional ability of 
RA patients [61]. Also, significant improvements in muscu-
lar strength may be attained with either a low-volume or a 
high-volume program [62]. Along with effectiveness, these 
programs are safe since, in well-controlled and recent-onset 
individuals with RA, application of high-intensity exercise 
regimes has been found to elicit significant improvements in 
neuromuscular performance, without aggravating joint pain 
or damage [63,64].
Apart from strength training, adopting a more active 
lifestyle can result in health benefits in conditions such as 
diabetes [65] and metabolic syndrome [66], and probably in 
RA. Most importantly, physically active individuals can main-
tain a higher level of physical functioning, reduce the rate of 
age-related muscle wasting [67], and improve life-satisfaction 
and well-being [68]. The effects of lifestyle changes in RA 
have not been investigated.
C O N C L U S I O N S
The exact mechanisms involved in the pathogenesis of 
RC remain unclear. In a synergistic manner TNFá and IL-1 
significantly enhance muscle catabolic processes but it remains 
unknown whether this is due to enhanced protein degradation 
or reduced protein re-synthesis. Reduced peripheral insulin 
activity and physical inactivity may also play a significant 
role in the maintenance and/or progression of this condition. 
Due to the fact that RC increases comorbidity and may be 
contributing to mortality, future research must focus on the 
understanding and prevention of this complication. Current 
preventive methods could include exercise programs and 
physically active lifestyles. The potentially beneficial effects 
of biological therapies need to be fully evaluated.
A C K N O W L E D G M E N T S
The work of the Cardiovascular Comorbidity Research 
Group is funded through grants from the Arthritis Research 
Campaign, NHS R&D and Dudley Group of Hospitals Research 
and Development Fund. George Metsios is a PhD student funded 
by the Greek State Scholarship Foundation (IKY) and Antonis 
Stavropoulos-Kalinoglou is a PhD student funded by the Uni-
versity of Wolverhampton.
R E F E R E N C E S
 1. Symmons DP. Epidemiology of rheumatoid arthritis: determi-
nants of onset, persistence and outcome. Best Pract Res Clin 
Rheumatol 2002; 16:707-722.
 2. Choy EH, Panayi GS. Cytokine pathways and joint inflamma-
tion in rheumatoid arthritis. N Engl J Med 2001; 344:907-916.
 3. Rall LC, Roubenoff R. Rheumatoid cachexia: metabolic abnor-
malities, mechanisms and interventions. Rheumatology 2004; 
43:1219-1223.
 4. Kitas GD, Erb N. Tackling ischaemic heart disease in rheuma-
toid arthritis. Rheumatology 2003; 42:607-613.
 5. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining 
how “high-grade” systemic inflammation accelerates vascular 
risk in rheumatoid arthritis. Circulation 2003; 108:2957-2963.
 6. Pincus T, Callahan LF, Sale WG, Brooks AL, et al. Severe func-
tional declines, work disability and increased mortality in 75 
rheumatoid arthritis patients studied over nine years. Arthritis 
Rheum 1984; 27:864-872.
 7. Pincus T, Callahan LF. Rheumatology function tests: grip 
strength, walking time, button test and questionnaires docu-
ment predict longterm morbidity and mortality in rheumatoid 
arthritis. J Rheumatol 1992; 19:1051-1057.
 8. Wallberg-Jonsson S, Johansson H, Ohman ML, Rantapaa-
Dahlqvist S. Extent of inflammation predicts cardiovascular dis-
ease and overall mortality in seropositive rheumatoid arthritis: a 
retrospective cohort study from disease onset. J Rheumatol 1999; 
26:2562-2571.
 9. Jacobsson LT, Turesson C, Hanson RL, Pillemer S, et al. Joint 
swelling as a predictor of death from cardiovascular disease in 
a population study of Pima Indians. Arthritis Rheum 2001; 44:
1170-1176.
 10. Chehata JC, Hassell AB, Clarke SA, Mattey DL, et al. Mortal-
ity in rheumatoid arthritis: relation to single and composite 
measures of disease activity. Rheumatology 2001; 40:447-452.
 11. Mitchell DM, Spitz PW, Young DY, Bloch DA, et al. Survival, 
prognosis, and causes of death in rheumatoid arthritis. Arthritis 
Rheum 1989; 29:706-714.
 12. Lehtinen K, Isomaki H. Intramuscular gold therapy is associ-
ated with long survival in patients with rheumatoid arthritis. J 
Rheumatol 1991; 18:524-529.
 13. Wallberg-Jonsson S, Ohman ML, Rantapaa-Dahlqvist S. Cardio-
vascular morbidity and mortality in patients with seropositive 
rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 
24:445-451.
 14. Krause D, Schleusser B, Herborn G, Rau R. Response to 
methotrexate treatment is associated with reduced mortality 
in patients with severe rheumatoid arthritis. Arthritis Rheum 
2000; 43:14-21.
 15. Choi HK, Herman MA, Seeger JD, Robins JM, et al. Metho-
trexate and mortality in patients with rheumatoid arthritis: a 
prospective study. Lancet 2002; 359:1173-1177.
 16. Roubenoff R, Roubenoff RA, Cannon JG, Kehayias JJ, et al. 
Rheumatoid cachexia: cytokine-driven hypermetabolism ac-
companying reduced body cell mass in chronic inflammation. J 
Clin Invest 1994; 93:2379-2386.
 17. Walsmith J, Abad L, Snydman L, Lundgren N, et al. Interleu-
kin-1b and tumor necrosis factor-a exhibit different metabolic 
effects in rheumatoid arthritis. Proc FASEB J 2000; 14:A525.
 18. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle 
24
HOSPITAL CHRONICLES 1(1), 2006 RHEUMATOID CACHEXIA: CAUSES, SIGNIFICANCE AND POSSIBLE INTERVENTIONS
25
protein breakdown and the critical role of the ubiquitin-protea-
some pathway in normal and disease states. J Nutr 1999a; 129:
227-237.
 19. Svenson KL, Lundqvist G, Wide L, Hallgren R. Impaired 
glucose handling in active rheumatoid arthritis: relationship 
to the secretion of insulin and counter-regulatory hormones. 
Metabolism 1997; 36:940-943.
 20. Paolisso G, Valentini G, Giugliano D, Marrazzo G, et al. Evi-
dence for peripheral impaired glucose handling in patients 
with connective tissue diseases. Metabolism 1991; 40:902-907.
 21. Cahill GF. Starvation in man. N Engl J Med 1972; 282:668-
675.
 22. Walsmith J, Roubenoff R. Cachexia in rheumatoid arthritis. Int 
J Cardiol 2002; 85:89-99.
 23. DeWys WD, Begg C, Lavin PT, Band PR, et al. Prognostic ef-
fect of weight loss prior to chemotherapy in cancer patients. 
Eastern Cooperative Oncology Group. Am J Med 1980; 69:
491-497.
 24. Kotler DP, Tierney AR, Pierson RN. Magnitude of body cell 
mass depletion and the timing of death from wasting in AIDS. 
Am J Clin Nutr 1989; 50:444-447.
 25. Gallagher D, Visser M, De Meersman RE, Sepulveda D, et al. 
Appendicular skeletal muscle mass: effects of age, gender, and 
ethnicity. J Appl Physiol 1997; 83:229-239.
 26. Roubenoff R, Hughes VA. Sarcopenia: current concepts. J 
Gerontol A Biol Sci Med Sci 2000; 55:716-724.
 27. Grunfeld C, Feingold KR. Metabolic disturbances and wast-
ing in the acquired immunodeficiency syndrome. N Engl J Med 
1992; 327:329-337.
 28. Paget J. Nervous mimicry of organic diseases. Lancet 1873; 2:
727–729.
 29. Munro R, Capell H. Prevalence of low body mass in rheuma-
toid arthritis: association with the acute phase response. Ann 
Rheum Dis 1997; 56:326-329.
 30. Westhovens R, Nijs J, Taelman V, Dequeker J. Body composi-
tion in rheumatoid arthritis. Br J Rheumatol 1997; 36:444-8.
 31. Arner P. Insulin resistance in type 2 diabetes - role of the adi-
pokines. Curr Mol Med 2005; 5:333-339.
 32. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J 
Allergy Clin Immunol 2005; 115:911-919.
 33. Poehlman ET. A review: exercise and its influence on resting 
energy metabolism in man. Med Sci Sports Exerc 1989; 21: 515- 
525.
 34. Poehlman ET, Toth MJ, Gardner AW. Changes in energy bal-
ance and body composition at menopause: a controlled longi-
tudinal study. Ann Intern Med 1995; 123:673-675.
 35. De Rossi M, Bernasconi P, Baggi F, de Waal Malefyt R, et 
al. Cytokines and chemokines are both expressed by human 
myoblasts: possible relevance for the immune pathogenesis of 
muscle inflammation. Int Immunol 2000; 12:1329-1335.
 36. Vassalli P. The pathophysiology of tumor necrosis factors. 
Annu Rev Immunol 1992; 10:411-452.
 37. Grell M, Douni E, Wajant H, Lohden M, et al. The transmem-
brane form of tumor necrosis factor is the prime activating 
ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995; 
83:793-802.
 38. Dinarello CA. Interleukin-1 and the pathogenesis of the acute-
phase response. N Engl J Med 1984; 311:1413-1418.
 39. Arend WP. Physiology of cytokine pathways in rheumatoid 
arthritis. Arthritis Rheum 2001; 45:101-106.
 40. Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The 
role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 
335:1897-1905.
 41. Lecker SH, Solomon V, Price SR, Kwon YT, et al. Ubiquitin 
conjugation by the N-end rule pathway and mRNAs for its 
components increase in muscles of diabetic rats. J Clin Invest 
1999b; 104:1411-1420.
 42. Li YP, Lecker SH, Chen Y, Waddell ID, et al. TNF-alpha 
increases ubiquitin-conjugating activity in skeletal muscle by 
up-regulating UbcH2/E220k. FASEB J 2003; 17:1048-1057.
 43. Guttridge DC, Mayo MW, Madrid LV, Wang CY, et al. NF-
kappaB-induced loss of MyoD messenger RNA: possible role 
in muscle decay and cachexia. Science 2000; 289:2363–2366.
 44. Langen RCJ, Schols AMWJ, Kelders MCJM, Wouters EFM, 
et al. Inflammatory cytokines inhibit myogenic differentiation 
through activation of nuclear factor-kappaB. FASEB J 2001; 15:
1169–1180.
 45. Hotamisligil GS, Murray DL, Choy LN, Spiegelman BM. Tu-
mor necrosis factor alpha inhibits signaling from the insulin 
receptor. Proc Natl Acad Sci USA 1994; 91:4854-4858.
 46. McArdle WD, Katch FI, Katch VL. Exercise Physiology: En-
ergy, Nutrition, and Human Performance 5th ed. Lippincott 
Williams, and Wilkins, USA, 2001.
 47. Garcia-Martinez C, Llovera M, Agell N, Lopez-Soriano FJ, et 
al. Ubiquitin gene expression in skeletal muscle is increased 
during sepsis: involvement of TNF-alpha but not IL-1. Biochem 
Biophys Res Commun 1995; 217:839-844.
 48. Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ, et 
al. Muscle wasting associated with cancer cachexia is linked to 
an important activation of the ATP-dependent ubiquitin-medi-
ated proteolysis. Int J Cancer 1995; 61:138-141.
 49. Roubenoff R, Hamada K, Vannier E, Cannon JG, et al. Cyto-
kine gene expression by skeletal muscle in adjuvant arthritis. 
Proc Arth Res Conf 2001:102.
 50. Kavuncu V, Evcik D. Physiotherapy in rheumatoid arthritis. 
Med Gen Med 2004; 6:3.
 51. Hall J, Grant J, Blake D, Taylor G, et al. Cardiorespiratory 
responses to aquatic treadmill walking in patients with rheu-
matoid arthritis. Physiother Res Int 2004; 9:59-73.
 52. Biolo G, Ciocchi B, Stulle M, Piccoli A, et al. Metabolic conse-
quences of physical inactivity. J Ren Nutr 2005; 15:49-53.
 53. Donohue RP, Abbott RD, Reed DM, Yano K. Physical activity 
and coronary heart disease in middle-aged and elderly men: 
The Honolulu heart program. Am J Public Health 1988; 78:
683-685.
 54. Lam TH, Ho SY, Hedley AJ, Mak KH, et al. Leisure time phys-
ical activity and mortality in Hong Kong: case-control study of 
all adult deaths in 1998. Ann Epidemiol 2004; 14:391-398
 55. Ramadan J, Barac-Nieto M. Low-frequency physical activity 
insufficient for aerobic conditioning is associated with lower 
26
HOSPITAL CHRONICLES 1(1), 2006
body fat than sedentary conditions. Nutrition 2001; 17:225-229.
 56. Minor MA, Lane NE. Recreational Exercise in Arthritis. 
Rheum Dis Clin North Am 1996; 22: 563-577.
 57. Westby MD. A health professional’s guide to exercise prescrip-
tion for people with arthritis: a review of aerobic fitness activi-
ties. Arthritis Rheum 2001; 45:501-511.
 58. Nordemar R, Ekblom B, Zachrisson L, Lundqvist K. Physical 
training in rheumatoid arthritis: A controlled long-term study. 
Scand J Rheumatol 1981; 10:17-23.
 59. Broeder CE, Burrhus KA, Svanevik LS, Wilmore JH. The ef-
fects of either high-intensity resistance or endurance training 
on resting metabolic rate. Am J Clin Nutr 1992; 55:802-810.
 60. Boshuizen HC, Stemmerik L, Westhoff MH, Hopman-Rock 
M. The effects of physical therapists’ guidance on improvement 
in a strength-training program for the frail elderly. J Aging Phys 
Act 2005; 13:5-22.
 61. de Jong Z, Munneke M, Zwinderman AH, Kroon HM, et al. Is 
a long-term high-intensity exercise program effective and safe 
in patients with rheumatoid arthritis? Results of a randomized 
controlled trial. Arthritis Rheum 2003; 48:2415-2424.
 62. Marx JO, Ratamess NA, Nindl BC, Gotshalk LA, et al. Low-
volume circuit versus high-volume periodized resistance train-
ing in women. Med Sci Sports Exerc 2001; 33:635-643.
 63. Hakkinen A, Hakkinen K, Hannonen P. Effects of strength 
training on neuromuscular function and disease activity in pa-
tients with recent-onset inflammatory arthritis. Scand J Rheumatol 
1994; 23:237-242.
 64. Rall LC, Meydani SN, Kehayias JJ, Dawson-Hughes B, et al. 
The effect of progressive resistance training in rheumatoid 
arthritis. Increased strength without changes in energy balance 
or body composition. Arthritis Rheum 1996; 39:415-426.
 65. Laaksonen DE, Lindstrom J, Lakka TA, Eriksson JG, et al. 
Physical activity in the prevention of type 2 diabetes: the fin-
nish diabetes prevention study. Diabetes 2005; 54:158-165.
 66. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and 
treatment of the metabolic syndrome. Angiology 2004; 55:589-
612.
 67. Fiatarone MA, O’Neill EF, Ryan ND, Clements KM, et al. 
Exercise training and nutritional supplementation for physical 
frailty in very elderly people. N Engl J Med 1994; 330:1769-
1775.
 68. Ohta M, Okufuji T, Matsushima Y, Ikeda M. The effect of 
lifestyle modification on physical fitness and work ability in 
different workstyles. J UOEH 2004; 26:411-421.
